Gland Pharma reported a strong Q2 FY26, with revenue up 6% year-on-year to INR14,869 million. The company anticipates an even stronger second half, driven by new product launches, volume growth, CDMO contract wins, and improvements at Cenexi. Adjusted EBITDA increased by 13%, and PAT by 12%. Focus remains on growth, capability, efficiency, and ROCE.
Financial Performance
In Q2 FY ’26, consolidated revenue reached INR14,869 million, a 6% increase from the previous year. EBITDA stood at INR3,139 million, also up by 6%. The company reported strong revenue growth in regulated markets, with the U.S. up by 10% and Europe by 16%. Cenexi’s revenue increased by 21% in rupee terms. For the first half of FY ’26, consolidated revenue reached INR29,925 million, a 7% increase, and EBITDA stood at INR6,817 million, with a margin of 23%, up from 20% in the prior year.
Business Segment Performance
In the U.S., seven molecules were launched in Q2 FY ’26, with revenue rising by 8% year-on-year to INR8,005 million. Other regulated markets generated revenue of INR462 million. Cenexi reported revenue of EUR 40 million for the quarter, an 8% increase, and year-to-date revenue stands at EUR 88 million, a 10% year-over-year increase in euro terms.
Strategic Focus and Initiatives
Gland Pharma is focused on expanding into a differentiated and complex portfolio, adding products centered on complex technologies. Key focus areas include long-acting injectables, hormones, suspensions, peptides, ready-to-use formats, and ophthalmic products. The company invested 5.8% of revenue in R&D this quarter, focusing on complex injectables and next-generation delivery systems.
CDMO Expansion
Biologic CDMO facility currently operates at 8 KL capacity. Plans are in place to expand to 23 KL to support biosimilar and biologic fill/finish opportunities. Cartridge fill/finish capacity is increasing from 40 million to 140 million units to support GLP-1 and insulin programs.
Guidance and Outlook
Gland Pharma anticipates an even stronger second half, supported by new product launches, volume growth, CDMO contract wins, and continued improvement at Cenexi. Full year revenue is expected to remain within mid-teens growth guidance.
Source: BSE
